| Budget Amount *help |
¥15,340,000 (Direct Cost: ¥11,800,000、Indirect Cost: ¥3,540,000)
Fiscal Year 2014: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2013: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
|
|---|
| Outline of Final Research Achievements |
We identified the association between hepatitis C virus (HCV)-induced hepatocellular carcinoma (HCC) and MICA single nucleotide polymorphism (SNP) by a genome wide association study (GWAS). Thus, we have aimed to analyze the function of MICA in HCV-induced HCC and to establish the way to prevent hepatocarcinogenesis through regulating MICA expression. First, the MICA SNP to regulate individual differences in MICA expression was examined, and two responsible SNPs were identified in the promoter region of MICA. Next, the drug to upregulate MICA was screened using HCC cells stably transfected by the reporter having MICA promoter region in its upstream and U.S. Food and Drug Administration (FDA)-approved drug library. SAHA most strongly upregulated MICA. Moreover, SAHA augmented NK cell cytotoxicity against HCC cells through upregulating MICA. Thus, SAHA could be the attractive option to treat HCV-induced HCC.
|
